ALBANY, N.Y., Nov. 29, 2016 /PRNewswire/ -- AMRI (NASDAQ:
AMRI) announced today that it has entered into a multi-year supply
agreement for an undisclosed product with Shire US Manufacturing,
Inc. which product has been in AMRI's portfolio through the
required stages of development. Shire plc, is a leading
global biotechnology company focused on developing and marketing
innovative medicines for patients with rare diseases and other
highly specialized conditions. The terms of the agreement are
confidential. This is the second such multi-year agreement
between AMRI and Shire, as AMRI has also been supplying a key
neuroscience product to Shire.
"This agreement builds on the long-standing development and
manufacturing relationship between Shire and AMRI," said
William S. Marth, President and CEO
of AMRI. "This long term contract with Shire illustrates our global
and growing integrated API contract manufacturing business well and
we look forward to continuing our relationship."
About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract
research and manufacturing organization that has been working with
the Life Sciences industry to improve patient outcomes and the
quality of life for more than two decades. With locations
in North America, Europe and Asia, our key
business segments include Discovery and Development Services (DDS),
Active Pharmaceutical Ingredients (API), Drug Product (DP), and
Fine Chemicals. For more information about AMRI, please visit our
website at www.amriglobal.com or follow us on Twitter
(@amriglobal).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-announces-api-supply-agreement-with-shire-300368811.html
SOURCE AMRI